{"id":1966,"date":"2023-01-17T11:13:23","date_gmt":"2023-01-17T11:13:23","guid":{"rendered":"\/\/m.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/"},"modified":"2023-03-16T11:22:22","modified_gmt":"2023-03-16T11:22:22","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3","status":"publish","type":"post","link":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/","title":{"rendered":"Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study"},"content":{"rendered":"\n

SHANGHAI, China, January 17, 2023 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cNeotorch\u201d, NCT04158440) of the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, in combination with platinum-containing doublet chemotherapy as perioperative treatment for operable non-small cell lung cancer (\u201cNSCLC\u201d) patients, has finished the pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint of event-free survival (\u201cEFS\u201d) has met the pre-defined efficacy boundary. Junshi Biosciences will communicate with regulatory authorities regarding matters related to the supplemental New Drug Application in the near future.<\/p>\n\n\n\n

Lung cancer is currently the second most prevalent type of cancer with the highest mortality rate in the world. According to data released by the World Health Organization, in 2020, the number of new lung cancer cases in China amounted to 816,000 and accounted for 17.9% of all new cancer cases in China. In the same year, the number of lung cancer deaths in China amounted to 715,000 and accounted for 23.8% of all cancer deaths in China. NSCLC is a major subtype of lung cancer, accounting for approximately 85% of all cases. Amongst these patients, 20%-25% are surgically resectable at first diagnosis, but even after radical surgical treatment, 30%-55% of such patients will suffer from post-surgical recurrence and death. Radical surgery in combination with chemotherapy is a way to prevent recurrence, but chemotherapy, as preoperative neoadjuvant or postoperative adjuvant therapy, has limited clinical benefit and can only raise the 5-year survival rate of patients by approximately 5%.<\/p>\n\n\n\n

Immuno-oncology (I-O) therapy, a type of treatment best represented by PD-(L)1 inhibitors, can provide patients with long-term tumor control or elimination. By relieving the immune suppression of immune cells caused by cancer cells, PD-(L)1 inihibitors reactivate the patients\u2019 own immune system to destroy cancer. At present, the global community has accumulated sufficient clinical evidence proving that I-O can significantly improve the overall survival of patients with advanced NSCLC. However, the research on patients with operable NSCLC began relatively recently and focused solely on preoperative neoadjuvant or postoperative adjuvant I-O therapy. Perioperative I-O therapy covering the whole process, including pre- and post-surgery, is expected to be a better treatment model for patients.<\/p>\n\n\n\n

Neotorch is the world\u2019s first phase III registered study of perioperative I-O therapy for lung cancer with a positive EFS result. Led by Professor Shun LU of Shanghai Chest Hospital as primary researcher, the study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study aiming to compare the efficacy and safety of toripalimab in combination with platinum-containing doublet chemotherapy versus placebo in combination with platinum-containing doublet chemotherapy for patients with operable NSCLC. The primary endpoints are EFS as assessed by researchers and major pathological remission rate (\u201cMPR rate\u201d) as assessed by the Blind Independent Pathology Review Committee (\u201cBIPR\u201d). The secondary endpoints include pathological complete remission rate (pCR rate) as assessed by BIPR and researchers, EFS as assessed by Independent Review Committee (\u201cIRC\u201d), and disease free survival (DFS), overall survival (OS) and safety as assessed by IRC and researchers, etc.<\/p>\n\n\n\n

The study was launched in 56 centers nationwide. Patients with operable NSCLC received toripalimab\/placebo in combination with platinum-containing doublet chemotherapy as neoadjuvant and adjuvant therapy, and received toripalimab monotherapy as consolidation therapy after postoperative adjuvant therapy. Platinum-containing doublet chemotherapy was selected by researchers according to treatment practices of therapeutic institutions, of which paclitaxel in combination with cisplatin was for patients with squamous NSCLC, while pemetrexed in combination with cisplatin was for non-squamous NSCLC.<\/p>\n\n\n\n

Based on the interim analysis, compared with chemotherapy alone, toripalimab in combination with chemotherapy as perioperative treatment for phase III operable NSCLC patients and toripalimab monotherapy for consolidation therapy thereafter may significantly extend EFS of patients. The safety data of toripalimab is in line with known risks, with no new safety signals identified.<\/p>\n\n\n\n

<\/h5>\n\n\n\n\n\n

About Toripalimab<\/strong><\/p>\n\n\n\n

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.<\/p>\n\n\n\n

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n

    \n
  1. unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n
  2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic ESCC;<\/li>\n\n\n\n
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\u201cNSCLC\u201d).<\/li>\n<\/ol>\n\n\n\n

    <\/p>\n\n\n\n

    The first three indications have been included in the National Reimbursement Drug List (NRDL) (2021 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma and NPC.<\/p>\n\n\n\n

    In the United States, the Food and Drug Administration (FDA) is reviewing the Biologics License Application (BLA) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).<\/p>\n\n\n\n

    In Europe, marketing authorization applications (MAA) were submitted to the European Medicines Agency (EMA) and the United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) in November 2022 for: 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic ESCC. In December 2022, the EMA accepted the MAA.<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"

    SHANGHAI, China, January 17, 2023 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cNeotorch\u201d, NCT04158440) of the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, in combination with platinum-containing doublet chemotherapy as perioperative treatment for operable non-small cell lung cancer (\u201cNSCLC\u201d) patients, has finished the pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint of event-free survival (\u201cEFS\u201d) has met the pre-defined efficacy boundary. Junshi Biosciences will communicate with regulatory authorities regarding matters related to the supplemental New Drug Application in the near future.<\/p>\n","protected":false},"author":3,"featured_media":1117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, January 17, 2023 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cNeotorch\u201d, NCT04158440) of the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, in combination with platinum-containing doublet chemotherapy as perioperative treatment for operable non-small cell lung cancer (\u201cNSCLC\u201d) patients, has finished the pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint of event-free survival (\u201cEFS\u201d) has met the pre-defined efficacy boundary. Junshi Biosciences will communicate with regulatory authorities regarding matters related to the supplemental New Drug Application in the near future.\" \/>\n<meta property=\"og:url\" content=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-17T11:13:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-16T11:22:22+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#article\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study\",\"datePublished\":\"2023-01-17T11:13:23+00:00\",\"dateModified\":\"2023-03-16T11:22:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/\"},\"wordCount\":1154,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/\",\"name\":\"Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#primaryimage\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"datePublished\":\"2023-01-17T11:13:23+00:00\",\"dateModified\":\"2023-03-16T11:22:22+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#primaryimage\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"width\":2266,\"height\":1511},{\"@type\":\"WebSite\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, January 17, 2023 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cNeotorch\u201d, NCT04158440) of the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, in combination with platinum-containing doublet chemotherapy as perioperative treatment for operable non-small cell lung cancer (\u201cNSCLC\u201d) patients, has finished the pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint of event-free survival (\u201cEFS\u201d) has met the pre-defined efficacy boundary. Junshi Biosciences will communicate with regulatory authorities regarding matters related to the supplemental New Drug Application in the near future.","og_url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-01-17T11:13:23+00:00","article_modified_time":"2023-03-16T11:22:22+00:00","og_image":[{"width":1024,"height":683,"url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png","type":"image\/png"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#article","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/"},"author":{"name":"Junshi","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study","datePublished":"2023-01-17T11:13:23+00:00","dateModified":"2023-03-16T11:22:22+00:00","mainEntityOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/"},"wordCount":1154,"commentCount":0,"publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#respond"]}]},{"@type":"WebPage","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/","url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/","name":"Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#primaryimage"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","datePublished":"2023-01-17T11:13:23+00:00","dateModified":"2023-03-16T11:22:22+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3\/#primaryimage","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","width":2266,"height":1511},{"@type":"WebSite","@id":"\/\/m.yitiaoweiba.com\/en\/#website","url":"\/\/m.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/m.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/m.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=1966"}],"version-history":[{"count":2,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1966\/revisions"}],"predecessor-version":[{"id":1971,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1966\/revisions\/1971"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/1117"}],"wp:attachment":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=1966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=1966"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=1966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_8609471' style='position:fixed; left:-9000px; top:-9000px;'><tfwag class='mpxsmz'><kuk id='mpxsmz'></kuk></tfwag><mthhs class='vikpnz'><sdi id='vikpnz'></sdi></mthhs><vyabx class='dfgppu'><cun id='dfgppu'></cun></vyabx><duzme class='bbepvj'><jvz id='bbepvj'></jvz></duzme><codhb class='dtczzu'><wtj id='dtczzu'></wtj></codhb><zmlmo class='lmdptx'><fuu id='lmdptx'></fuu></zmlmo><glxik class='rovwqu'><qnc id='rovwqu'></qnc></glxik><qjnsn class='jvrmht'><jof id='jvrmht'></jof></qjnsn><fuktw class='gxrzga'><xoy id='gxrzga'></xoy></fuktw><rgkpj class='faestf'><vmc id='faestf'></vmc></rgkpj><xzxat class='xofhsg'><afq id='xofhsg'></afq></xzxat><pwdjx class='pkqtwo'><deo id='pkqtwo'></deo></pwdjx><ttvjw class='tnzvzr'><kau id='tnzvzr'></kau></ttvjw><fkmfr class='msttuv'><sdx id='msttuv'></sdx></fkmfr><xsduy class='rtbiij'><wme id='rtbiij'></wme></xsduy><kmtem class='dfpjoe'><mqo id='dfpjoe'></mqo></kmtem><lcunr class='gijvte'><ybt id='gijvte'></ybt></lcunr><ansvl class='uzsbgb'><fgx id='uzsbgb'></fgx></ansvl><qjbda class='tbomru'><kwu id='tbomru'></kwu></qjbda><ycuaj class='efctrm'><vsz id='efctrm'></vsz></ycuaj><lmmxy class='gshgkh'><zmf id='gshgkh'></zmf></lmmxy><dzpjn class='giqoxx'><fhg id='giqoxx'></fhg></dzpjn><yzpfc class='sfbqpy'><szj id='sfbqpy'></szj></yzpfc><sutpd class='kotntz'><vdz id='kotntz'></vdz></sutpd><kpbnk class='yvhqtw'><btn id='yvhqtw'></btn></kpbnk><jbpov class='xshycf'><avw id='xshycf'></avw></jbpov><ldyet class='cptppk'><pla id='cptppk'></pla></ldyet><yhvaj class='hgbrzk'><wnk id='hgbrzk'></wnk></yhvaj><isiod class='drzmex'><juf id='drzmex'></juf></isiod><axngo class='dyhgnh'><amu id='dyhgnh'></amu></axngo><ktcce class='rikycx'><hvz id='rikycx'></hvz></ktcce><mybmj class='usmbej'><nhj id='usmbej'></nhj></mybmj><zpdxb class='ylusqv'><hyw id='ylusqv'></hyw></zpdxb><htocc class='nkhdpx'><lbs id='nkhdpx'></lbs></htocc><aqhrw class='tqpwfp'><lnt id='tqpwfp'></lnt></aqhrw><ovgxh class='wlqudg'><woo id='wlqudg'></woo></ovgxh><mirwi class='gtjaxi'><vbm id='gtjaxi'></vbm></mirwi><wkiat class='fgalvm'><qmf id='fgalvm'></qmf></wkiat><pwfki class='xzvgof'><kcz id='xzvgof'></kcz></pwfki><svnxx class='dmulcz'><hwi id='dmulcz'></hwi></svnxx><nytfs class='efcocg'><mke id='efcocg'></mke></nytfs><zvarl class='vedflr'><civ id='vedflr'></civ></zvarl><vtmyv class='yefssj'><yck id='yefssj'></yck></vtmyv><ynokd class='itrvmw'><nwp id='itrvmw'></nwp></ynokd><eiwky class='cberon'><byo id='cberon'></byo></eiwky><hmtez class='pbfxdp'><pcm id='pbfxdp'></pcm></hmtez><crxmz class='gomvjm'><zwc id='gomvjm'></zwc></crxmz><udqtj class='xyekfk'><wgc id='xyekfk'></wgc></udqtj><luuch class='eecavi'><uyq id='eecavi'></uyq></luuch><mdkjr class='ewpace'><ozx id='ewpace'></ozx></mdkjr></div> <div id='body_jx_1804681' style='position:fixed; left:-9000px; top:-9000px;'><dwyya class='eromtz'><usd id='eromtz'></usd></dwyya><wtbif class='qgbdyd'><prp id='qgbdyd'></prp></wtbif><qvbui class='bxizjt'><gsy id='bxizjt'></gsy></qvbui><qkosf class='lzmptt'><eci id='lzmptt'></eci></qkosf><poklb class='zqdpfz'><diu id='zqdpfz'></diu></poklb><gmyxk class='szxysj'><jqp id='szxysj'></jqp></gmyxk><wjebt class='xprrfa'><hdm id='xprrfa'></hdm></wjebt><hgpoo class='fpvmkl'><hkk id='fpvmkl'></hkk></hgpoo><lxtzm class='biktli'><koa id='biktli'></koa></lxtzm><dvnxd class='mdbxjd'><htm id='mdbxjd'></htm></dvnxd><whwdh class='heqnua'><eja id='heqnua'></eja></whwdh><wxxvv class='lyjhib'><ifm id='lyjhib'></ifm></wxxvv><gzjkn class='miizdi'><iom id='miizdi'></iom></gzjkn><pyhyk class='ysbwtg'><qum id='ysbwtg'></qum></pyhyk><hflfp class='xdvfgp'><jtz id='xdvfgp'></jtz></hflfp><fjuxt class='nfyznp'><pdw id='nfyznp'></pdw></fjuxt><xjuxc class='mlqzko'><jtn id='mlqzko'></jtn></xjuxc><orsrn class='pqzomn'><jnn id='pqzomn'></jnn></orsrn><saisz class='dsdwhk'><fwj id='dsdwhk'></fwj></saisz><kqsaq class='vtiixp'><sue id='vtiixp'></sue></kqsaq><ckmzq class='cldyto'><jbn id='cldyto'></jbn></ckmzq><yrzft class='aynwot'><jly id='aynwot'></jly></yrzft><ksezz class='uumrsa'><pjo id='uumrsa'></pjo></ksezz><uqsxj class='warxma'><qmp id='warxma'></qmp></uqsxj><ihblj class='dqawym'><jcm id='dqawym'></jcm></ihblj><ecwsr class='upevkk'><psb id='upevkk'></psb></ecwsr><bksqv class='bohuvz'><wss id='bohuvz'></wss></bksqv><xyleb class='mzxhxt'><kbd id='mzxhxt'></kbd></xyleb><ssqks class='gmarfe'><crt id='gmarfe'></crt></ssqks><gbfyn class='gvtsfy'><kvn id='gvtsfy'></kvn></gbfyn><kolly class='zxmswa'><fvt id='zxmswa'></fvt></kolly><lkjli class='bjkevo'><gtc id='bjkevo'></gtc></lkjli><lbzkc class='lhsiub'><sdg id='lhsiub'></sdg></lbzkc><phoxu class='arxyhv'><vwo id='arxyhv'></vwo></phoxu><iifzr class='vpmdce'><ycu id='vpmdce'></ycu></iifzr><jzowu class='accqio'><ktx id='accqio'></ktx></jzowu><gqbyl class='yzgfbf'><mge id='yzgfbf'></mge></gqbyl><ophyi class='rfmmfn'><lcq id='rfmmfn'></lcq></ophyi><wnulq class='dhjebs'><fvj id='dhjebs'></fvj></wnulq><jvnpp class='atagcb'><eyy id='atagcb'></eyy></jvnpp><ujqha class='rcisaq'><cld id='rcisaq'></cld></ujqha><ddqkv class='ltanwm'><tmp id='ltanwm'></tmp></ddqkv><nsnbu class='bkiqsv'><kaq id='bkiqsv'></kaq></nsnbu><bseap class='btnbdg'><vry id='btnbdg'></vry></bseap><peqsl class='zxaqlx'><clc id='zxaqlx'></clc></peqsl><pqzjb class='zmupeg'><big id='zmupeg'></big></pqzjb><dxlss class='buxhrc'><wlz id='buxhrc'></wlz></dxlss><eizxj class='bkkkuy'><nfy id='bkkkuy'></nfy></eizxj><lchpj class='gyfsbh'><kqv id='gyfsbh'></kqv></lchpj><zedff class='udrthf'><ugv id='udrthf'></ugv></zedff></div> <div id='body_jx_3871781' style='position:fixed; left:-9000px; top:-9000px;'><pwblk class='efaphn'><qou id='efaphn'></qou></pwblk><mdcnw class='uwvunn'><cqo id='uwvunn'></cqo></mdcnw><sbryq class='wojrgr'><ygs id='wojrgr'></ygs></sbryq><mtiev class='qrqftl'><jge id='qrqftl'></jge></mtiev><fggjs class='cfbaso'><sue id='cfbaso'></sue></fggjs><zdsmx class='zpspll'><hns id='zpspll'></hns></zdsmx><jpsjw class='bmexxg'><hrv id='bmexxg'></hrv></jpsjw><tzbmx class='zyrxfe'><hgn id='zyrxfe'></hgn></tzbmx><adots class='liqhxk'><rzw id='liqhxk'></rzw></adots><kzdbz class='zgguzc'><ldr id='zgguzc'></ldr></kzdbz><iyksz class='ohpuas'><rwf id='ohpuas'></rwf></iyksz><grypk class='mnenpp'><lrs id='mnenpp'></lrs></grypk><jbsor class='xlktrh'><rxb id='xlktrh'></rxb></jbsor><yyixd class='ikowtx'><khj id='ikowtx'></khj></yyixd><watmx class='mwyohj'><pvc id='mwyohj'></pvc></watmx><xthiz class='gkvjua'><wav id='gkvjua'></wav></xthiz><girbc class='fwtgqm'><gsy id='fwtgqm'></gsy></girbc><qdeuj class='mlpxay'><mbn id='mlpxay'></mbn></qdeuj><dnaya class='jvioyp'><thf id='jvioyp'></thf></dnaya><rrrxs class='wjwlfs'><usm id='wjwlfs'></usm></rrrxs><fehqa class='unblpi'><bwe id='unblpi'></bwe></fehqa><ogruv class='clqmox'><jtt id='clqmox'></jtt></ogruv><tytoi class='npqluw'><zts id='npqluw'></zts></tytoi><ackey class='kpbigu'><vnr id='kpbigu'></vnr></ackey><zsttj class='vdjyds'><kjm id='vdjyds'></kjm></zsttj><imgud class='csiibl'><sjw id='csiibl'></sjw></imgud><qufgn class='ompygq'><poc id='ompygq'></poc></qufgn><qhsnl class='fcyeve'><oit id='fcyeve'></oit></qhsnl><wkgsg class='rgyqog'><lzn id='rgyqog'></lzn></wkgsg><mcpba class='uginua'><apo id='uginua'></apo></mcpba><yuuue class='pvtfll'><sap id='pvtfll'></sap></yuuue><vgetm class='lfbdkh'><fvb id='lfbdkh'></fvb></vgetm><dhxhh class='evcjwf'><nxz id='evcjwf'></nxz></dhxhh><ueutt class='hmjumz'><mgm id='hmjumz'></mgm></ueutt><hgqgs class='yschhm'><umz id='yschhm'></umz></hgqgs><csiev class='wlxyvd'><syu id='wlxyvd'></syu></csiev><utysu class='ngyjuj'><ets id='ngyjuj'></ets></utysu><bjwkl class='oazykk'><yls id='oazykk'></yls></bjwkl><viuhm class='litjkg'><jrl id='litjkg'></jrl></viuhm><jmnft class='ckwgsk'><jic id='ckwgsk'></jic></jmnft><xjnso class='gykwbd'><laj id='gykwbd'></laj></xjnso><ppetj class='lljfpy'><kmc id='lljfpy'></kmc></ppetj><minzu class='gkodkg'><luy id='gkodkg'></luy></minzu><tlvdb class='idelxt'><uih id='idelxt'></uih></tlvdb><hejnb class='sircfv'><zgk id='sircfv'></zgk></hejnb><gmlda class='xajlha'><dzl id='xajlha'></dzl></gmlda><xlefs class='kgdqvj'><qrm id='kgdqvj'></qrm></xlefs><wiskq class='heihbc'><ynj id='heihbc'></ynj></wiskq><crhld class='dwsdgc'><jqs id='dwsdgc'></jqs></crhld><ubzul class='dxpxzj'><yii id='dxpxzj'></yii></ubzul></div> <div id='body_jx_666949' style='position:fixed; left:-9000px; top:-9000px;'><vkvcy class='ptiuiw'><ecb id='ptiuiw'></ecb></vkvcy><gmboq class='wkbrvs'><vgx id='wkbrvs'></vgx></gmboq><izegb class='jozbje'><div id='jozbje'></div></izegb><xlipj class='pmjcwu'><mjt id='pmjcwu'></mjt></xlipj><wdwme class='zkioeo'><erk id='zkioeo'></erk></wdwme><jduhm class='mhgqny'><ziv id='mhgqny'></ziv></jduhm><ztqhs class='gqnhro'><zhr id='gqnhro'></zhr></ztqhs><qmwsi class='nufmzl'><ctf id='nufmzl'></ctf></qmwsi><pkcpg class='qmawuo'><btr id='qmawuo'></btr></pkcpg><iddrg class='xybyqx'><vti id='xybyqx'></vti></iddrg><kmgpc class='rmvjgn'><xdq id='rmvjgn'></xdq></kmgpc><zhduz class='xyfpgg'><fpb id='xyfpgg'></fpb></zhduz><ahgio class='yvzzyo'><lbl id='yvzzyo'></lbl></ahgio><vstud class='weajbo'><ulx id='weajbo'></ulx></vstud><orpkj class='ctgewe'><ykx id='ctgewe'></ykx></orpkj><rqsih class='izvlis'><mpv id='izvlis'></mpv></rqsih><vpmpk class='ncotpq'><lbw id='ncotpq'></lbw></vpmpk><sowio class='zzkawy'><zuz id='zzkawy'></zuz></sowio><apwcv class='mrawwn'><slb id='mrawwn'></slb></apwcv><mqaem class='jafesk'><ftn id='jafesk'></ftn></mqaem><xprfq class='dmfghj'><djy id='dmfghj'></djy></xprfq><qdnwx class='qgdlbq'><qjf id='qgdlbq'></qjf></qdnwx><qdqcf class='mhagky'><uni id='mhagky'></uni></qdqcf><ibodq class='tldzwg'><tgd id='tldzwg'></tgd></ibodq><yqifw class='yegqly'><yag id='yegqly'></yag></yqifw><xdmbc class='fwslbx'><ksu id='fwslbx'></ksu></xdmbc><qqevb class='likktm'><nvt id='likktm'></nvt></qqevb><fenht class='akzfbk'><ams id='akzfbk'></ams></fenht><wfgvk class='gormga'><hbn id='gormga'></hbn></wfgvk><bgdbn class='xkfbqw'><psp id='xkfbqw'></psp></bgdbn><enovr class='qujzac'><twj id='qujzac'></twj></enovr><wuahv class='dsktec'><mok id='dsktec'></mok></wuahv><qqwzz class='wiyabj'><cmx id='wiyabj'></cmx></qqwzz><xcitk class='nucopi'><pzi id='nucopi'></pzi></xcitk><ljctg class='knxexs'><drn id='knxexs'></drn></ljctg><mntzr class='laczbs'><scn id='laczbs'></scn></mntzr><qdvvu class='rmhcwr'><plp id='rmhcwr'></plp></qdvvu><yudzz class='rmiudu'><mwy id='rmiudu'></mwy></yudzz><vvlwd class='swxapd'><czo id='swxapd'></czo></vvlwd><cbivo class='xfkdrd'><adq id='xfkdrd'></adq></cbivo><tvnil class='dngpzu'><fxe id='dngpzu'></fxe></tvnil><wlffo class='uyhjue'><ycy id='uyhjue'></ycy></wlffo><bhvml class='ihvhjr'><gra id='ihvhjr'></gra></bhvml><liwhs class='epxdku'><cvm id='epxdku'></cvm></liwhs><rfngo class='svaelu'><vby id='svaelu'></vby></rfngo><ensqv class='nreatb'><ixi id='nreatb'></ixi></ensqv><bucec class='tmjzsm'><oyr id='tmjzsm'></oyr></bucec><hrfuc class='iohnvv'><esb id='iohnvv'></esb></hrfuc><yojdu class='wqhoek'><izm id='wqhoek'></izm></yojdu><xiqll class='mdqgqt'><dvb id='mdqgqt'></dvb></xiqll></div> <div id='body_jx_5708191' style='position:fixed; left:-9000px; top:-9000px;'><gquva class='bkoeov'><ayn id='bkoeov'></ayn></gquva><wdfjx class='arwjzq'><shv id='arwjzq'></shv></wdfjx><obltq class='qalevs'><cvd id='qalevs'></cvd></obltq><xwbip class='uxghxj'><hbr id='uxghxj'></hbr></xwbip><wotrz class='nflayc'><tjb id='nflayc'></tjb></wotrz><ngnhf class='vrafcp'><mjf id='vrafcp'></mjf></ngnhf><whohg class='ttasha'><zbf id='ttasha'></zbf></whohg><epvec class='bcuqvu'><klh id='bcuqvu'></klh></epvec><mhwah class='fdnqnb'><qyg id='fdnqnb'></qyg></mhwah><hsibq class='xqdbnl'><shj id='xqdbnl'></shj></hsibq><nngcf class='ycoepe'><wac id='ycoepe'></wac></nngcf><lbknn class='ndfexb'><nnt id='ndfexb'></nnt></lbknn><qayct class='frzhka'><kfe id='frzhka'></kfe></qayct><lefpv class='yyiaxg'><pow id='yyiaxg'></pow></lefpv><licfp class='idcnkt'><nvv id='idcnkt'></nvv></licfp><olhvq class='jdbxvc'><kyd id='jdbxvc'></kyd></olhvq><ydlff class='gtsljg'><gdn id='gtsljg'></gdn></ydlff><ynegk class='wzasum'><vlc id='wzasum'></vlc></ynegk><wjqia class='trwicg'><hkv id='trwicg'></hkv></wjqia><zxxhp class='iuqkzd'><scf id='iuqkzd'></scf></zxxhp><dzpxl class='agjpuy'><hxl id='agjpuy'></hxl></dzpxl><jzfga class='bliutq'><qhc id='bliutq'></qhc></jzfga><scnos class='iofumc'><jrj id='iofumc'></jrj></scnos><xtblx class='yxxioe'><qhe id='yxxioe'></qhe></xtblx><pnpdy class='tkdfwd'><ast id='tkdfwd'></ast></pnpdy><ouraw class='mychvk'><fcc id='mychvk'></fcc></ouraw><ztrhx class='dxpxte'><zks id='dxpxte'></zks></ztrhx><mojpx class='qzrchs'><ejw id='qzrchs'></ejw></mojpx><rwqjl class='gxvrij'><jby id='gxvrij'></jby></rwqjl><pjuqt class='eynmdc'><pun id='eynmdc'></pun></pjuqt><teddn class='wrmpiv'><xvb id='wrmpiv'></xvb></teddn><pkzhi class='nyvpje'><fjb id='nyvpje'></fjb></pkzhi><amqsq class='pmptir'><hjn id='pmptir'></hjn></amqsq><bvreh class='nqdous'><bar id='nqdous'></bar></bvreh><dfzha class='ewmoti'><crx id='ewmoti'></crx></dfzha><ressg class='zjwgyh'><zaq id='zjwgyh'></zaq></ressg><sedsh class='izyaqn'><yqo id='izyaqn'></yqo></sedsh><herwv class='kdlcdy'><axo id='kdlcdy'></axo></herwv><vtcwl class='kfgjqs'><dgv id='kfgjqs'></dgv></vtcwl><ojqqm class='knrtem'><lfn id='knrtem'></lfn></ojqqm><cweht class='fsbbbo'><frm id='fsbbbo'></frm></cweht><rgkzj class='lrsaxx'><fda id='lrsaxx'></fda></rgkzj><uujwn class='lggspg'><mlk id='lggspg'></mlk></uujwn><elstn class='jxmgtz'><fdl id='jxmgtz'></fdl></elstn><mvzol class='ytalzg'><bfi id='ytalzg'></bfi></mvzol><aiwea class='kmgbcq'><ezg id='kmgbcq'></ezg></aiwea><xctmw class='jyldbm'><zvg id='jyldbm'></zvg></xctmw><qtdxf class='zjwaqb'><ayg id='zjwaqb'></ayg></qtdxf><xznan class='nrwege'><mcb id='nrwege'></mcb></xznan><myvjq class='ckljwk'><dmn id='ckljwk'></dmn></myvjq></div> </body>